Related Experiment Video
Updated: Jul 31, 2026
Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
Published on: September 27, 2013
Novel chimeric p16 and p27 molecules with increased antiproliferative activity for vascular disease gene therapy
1GPC Biotech Inc, Cambridge, MA 02139, USA.
Abstract:
We describe the construction and characterization of a series of novel cyclin-dependent kinase inhibitors with increased antiproliferative activity for use in the genetic treatment of hyperproliferative cell disorders, such as angioplasty-induced restenosis. These inhibitors were generated through the fusion of truncated versions of the p27 gene to the full-length p16 gene. Biochemically, the p27-p16 chimeric molecules were of comparable potency to the parental p27 in inhibiting the activities of several cyclin-dependent kinases in vitro. Replication-deficient adenoviruses encoding the parental p16, p27 genes, or their derivatives were created to assess the potency of the novel cyclin-dependent kinase inhibitor chimeric molecules to inhibit vascular smooth muscle cell proliferation, which is the seminal event in the restenosis process. One of the p27-p16 chimeric molecules, W9, was observed to be the most potent inhibitor of human primary smooth muscle and endothelial cell proliferation when compared to the p16, p27, p27 derivatives or several alternative p27-p16 chimeric molecules. Overexpression of the W9 chimeric molecule in human coronary artery smooth muscle cells induced human coronary artery smooth muscle cell growth arrest in G1 but did not induce cell apoptosis. Recombinant adenoviral vectors that express this W9 chimeric cyclin-dependent kinase inhibitor molecule constitute a novel potent antiproliferative agent for the treatment of restenosis.
Insights
Researchers developed novel cyclin-dependent kinase inhibitors by fusing p27 and p16 genes. The W9 inhibitor effectively reduced vascular smooth muscle cell proliferation, offering a potential treatment for restenosis.
Area of Science:
- Molecular Biology
- Genetics
- Cardiovascular Research
Background:
- Hyperproliferative cell disorders, like restenosis after angioplasty, involve uncontrolled cell growth.
- Cyclin-dependent kinases (CDKs) regulate the cell cycle and are targets for antiproliferative therapies.
Purpose of the Study:
- To create and characterize novel CDK inhibitors with enhanced antiproliferative activity.
- To evaluate these inhibitors for the genetic treatment of hyperproliferative disorders, specifically restenosis.
Main Methods:
- Constructed chimeric genes by fusing truncated p27 gene versions with the full-length p16 gene.
- Generated replication-deficient adenoviruses encoding p16, p27, and their chimeric derivatives.
- Assessed the inhibitory effects on vascular smooth muscle cell proliferation in vitro and in cell culture models.
Main Results:
- p27-p16 chimeric molecules showed comparable biochemical potency to parental p27 in inhibiting CDK activity.
- The W9 chimeric molecule demonstrated superior inhibition of human smooth muscle and endothelial cell proliferation compared to controls.
- W9 induced G1 cell cycle arrest in human coronary artery smooth muscle cells without causing apoptosis.
Conclusions:
- Novel p27-p16 chimeric CDK inhibitors possess significant antiproliferative potential.
- The W9 chimeric molecule is a potent inhibitor of vascular smooth muscle cell proliferation.
- Recombinant adenoviral vectors expressing W9 represent a promising therapeutic strategy for treating restenosis.
Related Concept Videos
00:59Gene Therapy
02:23Abnormal Proliferation
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy